Anzeige
Mehr »
Login
Montag, 31.03.2025 Börsentäglich über 12.000 News von 695 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A14M6X | ISIN: US04351P1012 | Ticker-Symbol: A71
Tradegate
26.03.25
15:14 Uhr
147,00 Euro
+4,00
+2,80 %
1-Jahres-Chart
ASCENDIS PHARMA A/S ADR Chart 1 Jahr
5-Tage-Chart
ASCENDIS PHARMA A/S ADR 5-Tage-Chart
RealtimeGeldBriefZeit
143,00145,0022:02
143,00145,0021:58

Aktuelle News zur ASCENDIS PHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrAscendis Pharma A/S - 6-K, Report of foreign issuer1
DoUBS maintains Ascendis Pharma stock Buy rating, $196 target1
DiHere's How Much $100 Invested In Ascendis Pharma 15 Years Ago Would Be Worth Today1
20.03.Ascendis Pharma A/S - 6-K, Report of foreign issuer2
12.03.Ascendis Pharma A/S - 6-K, Report of foreign issuer3
27.02.Ascendis Pharma A/S - S-8, Securities to be offered to employees in employee benefit plans1
25.02.Cantor Fitzgerald lifts Ascendis Pharma target to $200, maintains Overweight3
ASCENDIS PHARMA Aktie jetzt für 0€ handeln
13.02.Why Is Rare Disease Focused Ascendis Pharma Stock Trading Higher On Thursday?4
13.02.Ascendis Pharma targets €200M SKYTROFA revenue and expands YORVIPATH globally in 20253
12.02.Ascendis Pharma parks $25M for buyback program, net settlement of certain RSUs2
12.02.Ascendis Pharma launches $25 million share buyback2
12.02.Ascendis Pharma A/S Announces Share Repurchase Program & Net Settlement of Certain RSUs1
12.02.Ascendis Pharma Reports Fourth Quarter and Full Year 2024 Financial Results501- Strong early U.S. YORVIPATH® launch with 908 prescriptions as of Feb. 7, 2025; YORVIPATH full year 2024 revenue of €28.7 million - Following pre-NDA meeting with FDA, on track to submit TransCon...
► Artikel lesen
12.02.Ascendis Pharma A/S - 20-F, Annual and transition report of foreign private issuers-
12.02.Ascendis Pharma A/S - 6-K, Report of foreign issuer1
11.02.Ascendis Pharma A/S (NASDAQ:ASND) Given "Overweight" Rating at Cantor Fitzgerald1
05.02.Ascendis Pharma to Report Full Year 2024 Financial Results and Provide Business Update on February 12, 20251
23.01.Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Years6
15.01.Ascendis Pharma A/S - 6-K, Report of foreign issuer-
13.01.Ascendis Pharma stock falls on missed Skytrofa revenue forecast15
Seite:  Weiter >>
49 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1